Department of Integrative Physiology, University of Colorado Boulder, Boulder, Colorado, USA.
Department of Kinesiology and Applied Physiology, University of Delaware, Newark, Delaware, USA.
J Gerontol A Biol Sci Med Sci. 2023 Dec 1;78(12):2435-2448. doi: 10.1093/gerona/glad106.
Advancing age and many disease states are associated with declines in nicotinamide adenine dinucleotide (NAD+) levels. Preclinical studies suggest that boosting NAD+ abundance with precursor compounds, such as nicotinamide riboside or nicotinamide mononucleotide, has profound effects on physiological function in models of aging and disease. Translation of these compounds for oral supplementation in humans has been increasingly studied within the last 10 years; however, the clinical evidence that raising NAD+ concentrations can improve physiological function is unclear. The goal of this review was to synthesize the published literature on the effects of chronic oral supplementation with NAD+ precursors on healthy aging and age-related chronic diseases. We identified nicotinamide riboside, nicotinamide riboside co-administered with pterostilbene, and nicotinamide mononucleotide as the most common candidates in investigations of NAD+-boosting compounds for improving physiological function in humans. Studies have been performed in generally healthy midlife and older adults, adults with cardiometabolic disease risk factors such as overweight and obesity, and numerous patient populations. Supplementation with these compounds is safe, tolerable, and can increase the abundance of NAD+ and related metabolites in multiple tissues. Dosing regimens and study durations vary greatly across interventions, and small sample sizes limit data interpretation of physiological outcomes. Limitations are identified and future research directions are suggested to further our understanding of the potential efficacy of NAD+-boosting compounds for improving physiological function and extending human health span.
随着年龄的增长和许多疾病状态的出现,烟酰胺腺嘌呤二核苷酸(NAD+)水平会下降。临床前研究表明,用前体化合物(如烟酰胺核糖或烟酰胺单核苷酸)来提高 NAD+的丰度,对衰老和疾病模型中的生理功能有深远的影响。在过去的 10 年中,这些化合物被越来越多地研究用于口服补充,以提高 NAD+浓度是否能改善生理功能的临床证据尚不清楚。本综述的目的是综合已发表的关于慢性口服补充 NAD+前体对健康衰老和与年龄相关的慢性疾病影响的文献。我们确定烟酰胺核糖、烟酰胺核糖与白藜芦醇联合使用以及烟酰胺单核苷酸是研究提高 NAD+水平以改善人类生理功能的最常见候选化合物。这些研究在一般健康的中年和老年人、有超重和肥胖等心血管代谢疾病风险因素的成年人以及许多患者人群中进行。这些化合物的补充是安全的,耐受性良好,可以增加多个组织中 NAD+和相关代谢物的丰度。干预措施的剂量方案和研究持续时间差异很大,样本量小限制了对生理结果的数据分析。本文确定了局限性并提出了未来的研究方向,以进一步了解提高 NAD+水平的化合物在改善生理功能和延长人类健康寿命方面的潜在疗效。